Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Multiforme Prior to and After Secondary Resection: an Open-label Phase I/II Trial.
Prior to and after re-operation patients with recurrent glioblastoma receive the
investigational drug Patupilone, a tubulin-inhibitor.
The purpose of the trial is to prolong PFS in this patient population. Patupilone is already
used in clinical trials of other tumor entities such as ovarian cancer, breast and lung
cancer. Side effects are expected to be manageable.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival
Silvia Hofer, MD